Oruka Therapeutics, Inc. ORKA

Oruka Therapeutics announced Week 28 data from EVERLAST-A evaluating ORKA-001 in adults with moderate-to-severe plaque psoriasis. Efficacy continued to improve after week 4 dosing, with PASI100 at Week 28 rising to 71.4% (45 of 63), PASI90 to 87.3% and IGA 0/1 at 84.1% (53 of 63). Among placebo crossover patients, 40% achieved PASI100 at Week 28, broadly comparable to the 42.9% in initially treated patients. ORKA-001, a half-life extended IL-23p19 antibody, was generally well tolerated; only an 8% rate of URIs and two SAEs occurred but were deemed unrelated to the drug. Oruka plans 52-week EVERLAST-A results in December 2026 and a Phase IIb EVERLAST-B readout in Q4 2026 to inform a Phase III in 2027, while pursuing other programs (ORKA-002, ORKA-004). The stock declined about 5% on safety disclosures. Durable week-28 efficacy and upcoming pivotal trial plans could meaningfully boost long-term prospects, despite a near-term sentiment hit from safety disclosures.

UBS says Oruka Therapeutics' lead long-acting IL-23 therapy for moderate-to-severe psoriasis maintains a competitive profile after positive clinical data. The note highlights the candidate's continued positioning in a crowded psoriasis market and points to potential near-term catalysts such as additional trial readouts and potential partner discussions. UBS treats the data as supportive but not transformative, suggesting the program could see continued investor interest as ORKA advances toward later-stage development and potential commercialization, subject to ongoing safety and efficacy results. Positive data preserving competitive standing could modestly support valuation and investor sentiment without signaling a major breakthrough.

Oruka Therapeutics shares fell 5% after Week 28 results from EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe plaque psoriasis. The trial enrolled 84 patients across 26 sites in the U.S. and Canada, with a 3:1 randomization to ORKA-001 600 mg at Weeks 0 and 4 versus placebo; placebo-treated patients crossed over to active treatment at Week 16. At Week 28, PASI 100 responses reached 71.4% (up from 63.5% at Week 16), and PASI 90 responses were 87.3%. Responses continued to improve six months after the final dose, without further treatment after Week 4, per Oruka. Safety through Week 28 aligned with the IL-23p19 class, with 8% experiencing upper respiratory tract infection; two SAEs were reported but not linked to ORKA-001. Full 52-week data expected December 2026, with EVERLAST-B data later in Q4 2026. Positive Week 28 efficacy signals and upcoming longer-term readouts could meaningfully influence development trajectory and investor sentiment.

Oruka Therapeutics reported Week 28 results from EVERLAST-A, a Phase 2a trial of ORKA-001, a half-life extended IL-23p19 antibody for moderate-to-severe plaque psoriasis. Among 63 patients treated with ORKA-001, PASI 100 reached 71.4% and PASI 90 87.3% at Week 28, up from Week 16, with no dosing after Week 4. Placebo-crossed patients (n=20) who began ORKA-001 at Week 16/20 achieved 40.0% PASI 100 at Week 28, similar to 42.9% in the initial ORKA-001 group at the same timepoint. IGA 0/1 responses remained at 84.1%. ORKA-001 was generally well tolerated; the only ≥5% adverse event was upper respiratory tract infection (8%). Two SAEs occurred but were not drug-related. Data support durable clearance with infrequent dosing; longer-term Week 52 data expected December 2026, with EVERLAST-B Phase 2b data expected in Q4 2026. Durable high clearance rates after only two doses plus a safety profile consistent with IL-23p19 indicate meaningful upside but ultimate success depends on Phase 3 outcomes.

Oruka Therapeutics reported Week 28 data from EVERLAST-A Phase 2a for ORKA-001 in moderate-to-severe plaque psoriasis, showing deepening PASI responses and a safety profile aligned with the IL-23p19 class. Placebo patients who crossed over to ORKA-001 after delaying treatment showed similar response trajectories, underscoring potential efficacy even with late initiation. The company frames ORKA-001 as potentially carving a niche in a crowded IL-23 market while it funds late-stage development without crushing existing holders. Near-term catalysts include fuller 52-week data in 2026 and the EVERLAST-B Phase 2b readout in 2027. Key risks remain: no revenue, rising losses, recent equity dilution, a relatively new board, and a long runway to commercial cash flow. Valuation debates among analysts suggest the stock may be overvalued given the cash burn and uncertainties. Positive phase 2a signals could lift sentiment and catalysts, but lack of revenue and ongoing dilution limit upside.

Oruka Therapeutics reported week 28 results from its Phase 2a trial of ORKA-001 for moderate-to-severe plaque psoriasis. At week 16, 63.5% of treated patients achieved PASI-100; by week 28, PASI-100 rose to 71.4% and PASI-90 to 87.3%, with IGA 0/1 responses at 84.1%. Crossover patients in weeks 16-28 showed similar gains; 12 weeks after initial dosing, 40% reached PASI-100, aligning with active-arm results at the same point. ORKA-001 maintained a safety profile expected for IL-23p19 monoclonal antibodies; upper respiratory infections were the only adverse event >5% between weeks 16 and 28. Two serious adverse events occurred (tibial fracture, prostate cancer risk) but were deemed unrelated to the drug. The EVERLAST-A study will follow patients to 52 weeks with long-term data due December 2026; EVERLAST-B Phase 2b data expected Q4 2026. Shares were down 0.3% to $94.26 at publication. Robust Phase 2a efficacy and favorable safety could lift near-term sentiment, but no Phase 3 data yet limits long-term upside.

H.C. Wainwright reaffirms Buy rating on Oruka Therapeutics (ORKA) following Apogee acquisition news. Apogee acquisition marks major strategic expansion for Oruka backed by sustained analyst Buy rating.

Oruka Therapeutics (ORKA) faces valuation review following psoriasis trial progress, new partnerships, and recent funding. Psoriasis trial advancements, partnerships, and fresh funding boost ORKA's pipeline, resources, and investor appeal significantly.

A biotech fund added $7 million to its position in Oruka Therapeutics (ORKA), an oncology stock that has surged 120%. Substantial fund investment signals strong confidence in ORKA's oncology prospects amid 120% gains, likely boosting investor sentiment and stock trajectory.

Biotech fund initiates $9 million position in newly public Oruka Therapeutics (ORKA), a cancer-focused company, signaling confidence in its vitiligo and skin disease treatments amid recent IPO. $9M stake by biotech fund boosts investor sentiment and liquidity for newly public ORKA, potentially driving significant short-term stock gains and long-term validation.

A biotech fund boosted its stake in Oruka Therapeutics (ORKA) amid the stock's staggering 500% rally, signaling strong confidence in the company's prospects. Major fund's increased stake during 500% rally reinforces investor confidence and positively influences market sentiment and trajectory.

Oruka Therapeutics, Inc. (ORKA) reported first quarter 2026 financial results and provided a corporate update. Quarterly financial results combined with corporate updates typically signal major strategic developments that significantly impact biotech stock performance and investor sentiment.

Oruka Therapeutics, a small biotech, outperformed AbbVie's $17 billion drug, raising questions for investors on implications. Outperforming AbbVie's blockbuster drug positions Oruka as a transformative contender in the market.

Oruka Therapeutics (ORKA) shares dropped 6.3% following a $700 million follow-on offering announcement amid a breakthrough in psoriasis treatment. $700 million follow-on provides major funding to advance psoriasis breakthrough, significantly impacting ORKA's development and market trajectory despite short-term dilution.

Halozyme and Oruka Therapeutics, Inc. (ORKA) signed an agreement for Halozyme's Hypercon technology, enabling subcutaneous delivery for Oruka's immunology portfolio. Licensing Halozyme's Hypercon technology accelerates Oruka's drug delivery, validates its pipeline, and likely drives positive investor sentiment.

Halozyme and Oruka Therapeutics announce global collaboration and license agreement to develop ORKA-001 using Halozyme's Hypercon™ Technology. Global partnership with Halozyme enables Hypercon™ delivery for ORKA-001, accelerating development and enhancing commercial prospects.

Oruka Therapeutics (ORKA) reports positive Phase 2a results for ORKA-001, its investigational psoriasis treatment. Positive Phase 2a data for lead psoriasis candidate ORKA-001 advances clinical pipeline significantly, likely boosting investor sentiment and market performance.

Oruka Therapeutics priced an upsized $700 million underwritten public offering. $700 million upsized offering provides transformative capital for pipeline advancement and long-term prospects.

Oruka Therapeutics (ORKA) stock surged to a record high after stellar clinical trial results. Stellar clinical trial results drove ORKA to record stock highs, poised to redefine its competitive position and long-term prospects.

Oruka Therapeutics, a small biotech, disrupted AbbVie's $18 billion franchise with promising developments challenging its psoriasis market dominance. Oruka's breakthrough rattles AbbVie's psoriasis stronghold, fundamentally boosting ORKA's competitive edge and long-term prospects.

Oruka Therapeutics highlights 'category-winning' data for ORKA-001, advancing toward once-yearly dosing for psoriasis treatment. Strong clinical data and innovative once-yearly dosing for ORKA-001 position Oruka as a leader in psoriasis therapy, driving significant investor interest and valuation upside.

Oruka Therapeutics, Inc. (ORKA) announces a proposed $500 million underwritten public offering of common stock. A $500 million public offering delivers substantial capital for pipeline advancement and operational runway, significantly enhancing ORKA's growth trajectory and investor confidence.

Oruka Therapeutics' psoriasis drug achieves complete skin clearance in 64% of patients. Strong clinical efficacy data for the lead psoriasis drug could significantly advance regulatory approval, partnerships, and stock performance.

Oruka Therapeutics (ORKA) shares surged following strong results from a psoriasis clinical trial. Strong psoriasis trial results triggered share price jump, positioning Oruka for potential regulatory progress and market expansion.

Oruka Therapeutics Inc. (ORKA) shares surged after early data demonstrated promise for their long-acting psoriasis drug, highlighting potential in treating the condition with fewer doses. Early promising results from Oruka's long-acting psoriasis drug triggered a stock surge, positioning it for major pipeline advancements and heightened investor interest.

Oruka Therapeutics announced positive Week 16 data for ORKA-001 from the ongoing EVERLAST-A Phase 2a trial in moderate-to-severe plaque psoriasis. Positive Phase 2a trial data for ORKA-001 signals strong efficacy in psoriasis, likely driving significant stock gains and pipeline advancement.

Oruka Therapeutics will host a conference call on April 27, 2026, to report Week 16 data for ORKA-001 from the ongoing EVERLAST-A trial. Week 16 data from the EVERLAST-A trial for ORKA-001 is a major clinical milestone that could significantly sway investor sentiment and ORKA's trajectory.

Wedbush raised its price target for Oruka Therapeutics (ORKA) from $45 to $85. Wedbush nearly doubling its price target indicates significant positive shift in analyst sentiment, likely boosting investor confidence and stock performance.

Oruka Therapeutics, Inc. (ORKA) stock surges after positive results from its startup's psoriasis drug studies. Positive psoriasis drug study results lifted ORKA's stock, signaling major clinical progress with potential to alter biotech trajectory.

Oruka Therapeutics (ORKA) stock has surged nearly 840% in the past year and carries a 'Strong Buy' rating, raising questions about additional growth potential. Massive 840% stock gain and 'Strong Buy' rating boost investor sentiment and could drive further market performance.